Cargando…

Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -A study of the OVCAD consortium

BACKGROUND: The role of the tumor necrosis factor receptor associated protein 1 (TRAP1) – supposed to be involved in protection of cells from apoptosis and oxidative stress – has just started to be investigated in ovarian cancer. TRAP1 has been shown to be estrogen up-regulated in estrogen receptor...

Descripción completa

Detalles Bibliográficos
Autores principales: Aust, Stefanie, Bachmayr-Heyda, Anna, Pateisky, Petra, Tong, Dan, Darb-Esfahani, Silvia, Denkert, Carsten, Chekerov, Radoslav, Sehouli, Jalid, Mahner, Sven, Van Gorp, Toon, Vergote, Ignace, Speiser, Paul, Horvat, Reinhard, Zeillinger, Robert, Pils, Dietmar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3533746/
https://www.ncbi.nlm.nih.gov/pubmed/22978347
http://dx.doi.org/10.1186/1476-4598-11-69
_version_ 1782254447297036288
author Aust, Stefanie
Bachmayr-Heyda, Anna
Pateisky, Petra
Tong, Dan
Darb-Esfahani, Silvia
Denkert, Carsten
Chekerov, Radoslav
Sehouli, Jalid
Mahner, Sven
Van Gorp, Toon
Vergote, Ignace
Speiser, Paul
Horvat, Reinhard
Zeillinger, Robert
Pils, Dietmar
author_facet Aust, Stefanie
Bachmayr-Heyda, Anna
Pateisky, Petra
Tong, Dan
Darb-Esfahani, Silvia
Denkert, Carsten
Chekerov, Radoslav
Sehouli, Jalid
Mahner, Sven
Van Gorp, Toon
Vergote, Ignace
Speiser, Paul
Horvat, Reinhard
Zeillinger, Robert
Pils, Dietmar
author_sort Aust, Stefanie
collection PubMed
description BACKGROUND: The role of the tumor necrosis factor receptor associated protein 1 (TRAP1) – supposed to be involved in protection of cells from apoptosis and oxidative stress – has just started to be investigated in ovarian cancer. TRAP1 has been shown to be estrogen up-regulated in estrogen receptor α (ERα) positive ovarian cancer cells. The clinical impact of TRAP1 is not clear so far and the significance of ERα expression as therapeutic and prognostic marker is still controversial. Therefore, we investigated the importance of TRAP1 together with ERα in regard to clinicopathological parameters, chemotherapy response, and survival. METHODS AND RESULTS: Expressions of TRAP1 and ERα were evaluated by immunohistochemical staining of tissue microarrays comprised of 208 ovarian cancer samples. TRAP1 was highly expressed in 55% and ERα was expressed in 52% of all cases. High TRAP1 expression correlated significantly with ERα (p < 0.001) but high TRAP1 expression was also found in 42% of ERα negative cases. High TRAP1 expression correlated significantly with favorable chemotherapy-response (HR = 0.48; 95%CI 0.24-0.96, p=0.037) and showed a significant impact on overall survival (OS) (HR = 0.65; 95%CI 0.43-0.99, p = 0.044). ERα expression was a favorable prognostic factor for OS in univariate and multivariate analyses. Interestingly, the combined pattern (ERα positive and/or TRAP1-high) revealed the strongest independent and significant positive influence on OS (HR = 0.41; 95%CI 0.27-0.64). CONCLUSION: Immunohistochemical evaluation of TRAP1 together with ERα provides significant prognostic information. TRAP1 alone is significantly associated with chemotherapy response and overall survival, rendering TRAP1 as interesting scientific and therapeutic target.
format Online
Article
Text
id pubmed-3533746
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35337462013-01-03 Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -A study of the OVCAD consortium Aust, Stefanie Bachmayr-Heyda, Anna Pateisky, Petra Tong, Dan Darb-Esfahani, Silvia Denkert, Carsten Chekerov, Radoslav Sehouli, Jalid Mahner, Sven Van Gorp, Toon Vergote, Ignace Speiser, Paul Horvat, Reinhard Zeillinger, Robert Pils, Dietmar Mol Cancer Research BACKGROUND: The role of the tumor necrosis factor receptor associated protein 1 (TRAP1) – supposed to be involved in protection of cells from apoptosis and oxidative stress – has just started to be investigated in ovarian cancer. TRAP1 has been shown to be estrogen up-regulated in estrogen receptor α (ERα) positive ovarian cancer cells. The clinical impact of TRAP1 is not clear so far and the significance of ERα expression as therapeutic and prognostic marker is still controversial. Therefore, we investigated the importance of TRAP1 together with ERα in regard to clinicopathological parameters, chemotherapy response, and survival. METHODS AND RESULTS: Expressions of TRAP1 and ERα were evaluated by immunohistochemical staining of tissue microarrays comprised of 208 ovarian cancer samples. TRAP1 was highly expressed in 55% and ERα was expressed in 52% of all cases. High TRAP1 expression correlated significantly with ERα (p < 0.001) but high TRAP1 expression was also found in 42% of ERα negative cases. High TRAP1 expression correlated significantly with favorable chemotherapy-response (HR = 0.48; 95%CI 0.24-0.96, p=0.037) and showed a significant impact on overall survival (OS) (HR = 0.65; 95%CI 0.43-0.99, p = 0.044). ERα expression was a favorable prognostic factor for OS in univariate and multivariate analyses. Interestingly, the combined pattern (ERα positive and/or TRAP1-high) revealed the strongest independent and significant positive influence on OS (HR = 0.41; 95%CI 0.27-0.64). CONCLUSION: Immunohistochemical evaluation of TRAP1 together with ERα provides significant prognostic information. TRAP1 alone is significantly associated with chemotherapy response and overall survival, rendering TRAP1 as interesting scientific and therapeutic target. BioMed Central 2012-09-14 /pmc/articles/PMC3533746/ /pubmed/22978347 http://dx.doi.org/10.1186/1476-4598-11-69 Text en Copyright ©2012 Aust et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Aust, Stefanie
Bachmayr-Heyda, Anna
Pateisky, Petra
Tong, Dan
Darb-Esfahani, Silvia
Denkert, Carsten
Chekerov, Radoslav
Sehouli, Jalid
Mahner, Sven
Van Gorp, Toon
Vergote, Ignace
Speiser, Paul
Horvat, Reinhard
Zeillinger, Robert
Pils, Dietmar
Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -A study of the OVCAD consortium
title Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -A study of the OVCAD consortium
title_full Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -A study of the OVCAD consortium
title_fullStr Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -A study of the OVCAD consortium
title_full_unstemmed Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -A study of the OVCAD consortium
title_short Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -A study of the OVCAD consortium
title_sort role of trap1 and estrogen receptor alpha in patients with ovarian cancer -a study of the ovcad consortium
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3533746/
https://www.ncbi.nlm.nih.gov/pubmed/22978347
http://dx.doi.org/10.1186/1476-4598-11-69
work_keys_str_mv AT auststefanie roleoftrap1andestrogenreceptoralphainpatientswithovariancancerastudyoftheovcadconsortium
AT bachmayrheydaanna roleoftrap1andestrogenreceptoralphainpatientswithovariancancerastudyoftheovcadconsortium
AT pateiskypetra roleoftrap1andestrogenreceptoralphainpatientswithovariancancerastudyoftheovcadconsortium
AT tongdan roleoftrap1andestrogenreceptoralphainpatientswithovariancancerastudyoftheovcadconsortium
AT darbesfahanisilvia roleoftrap1andestrogenreceptoralphainpatientswithovariancancerastudyoftheovcadconsortium
AT denkertcarsten roleoftrap1andestrogenreceptoralphainpatientswithovariancancerastudyoftheovcadconsortium
AT chekerovradoslav roleoftrap1andestrogenreceptoralphainpatientswithovariancancerastudyoftheovcadconsortium
AT sehoulijalid roleoftrap1andestrogenreceptoralphainpatientswithovariancancerastudyoftheovcadconsortium
AT mahnersven roleoftrap1andestrogenreceptoralphainpatientswithovariancancerastudyoftheovcadconsortium
AT vangorptoon roleoftrap1andestrogenreceptoralphainpatientswithovariancancerastudyoftheovcadconsortium
AT vergoteignace roleoftrap1andestrogenreceptoralphainpatientswithovariancancerastudyoftheovcadconsortium
AT speiserpaul roleoftrap1andestrogenreceptoralphainpatientswithovariancancerastudyoftheovcadconsortium
AT horvatreinhard roleoftrap1andestrogenreceptoralphainpatientswithovariancancerastudyoftheovcadconsortium
AT zeillingerrobert roleoftrap1andestrogenreceptoralphainpatientswithovariancancerastudyoftheovcadconsortium
AT pilsdietmar roleoftrap1andestrogenreceptoralphainpatientswithovariancancerastudyoftheovcadconsortium